Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that in healthy young men, oral minoxidil at 5 mg/day led to increased carotid intima-media thickness and vascular aging, suggesting potential cardiovascular side effects at higher doses. A dose-dependent effect was observed, while dutasteride displayed a favorable vascular profile without significant changes.

This study identified CD28, GZMB, and CD1C as key immune regulators in alopecia areata, highlighting CD28 as a potential therapeutic target with a promising safety profile, using a proteome-anchored multi-omics approach to uncover actionable targets for this autoimmune hair-loss disorder.

This review highlights the increasing global incidence and broad socio-economic impact of celiac disease, emphasizing the need for improved recognition and management to address its multidimensional implications, including comorbidities and dietary challenges.

In this study, oral etretinate resulted in increased hair length and loss of beading in a childhood monilethrix case, while the scalp's keratosis pilaris persisted.

This study reported that inhibiting the JAK-STAT pathway with baricitinib restored cellular homeostasis, delayed senescence, and reduced proinflammatory markers in Hutchinson-Gilford progeria syndrome cell models.

This review examines the definition, classification, mechanism, clinical efficacy for hair regrowth, and potential adverse effects of platelet rich plasma, but does not present new experimental results.

This review analyzed 17 recent clinical trials on platelet-rich plasma for androgenetic alopecia but reports no new clinical results; the authors seek a consensus on optimal PRP use.

This review discusses regenerative medicine's applications in dermatology, highlighting the need for quality clinical trials to optimize treatments like PRP, stem cells, and exosomes, and reports no new results.

In this study, trichoscopy was found to enhance the early assessment of minoxidil therapy in males with pattern hair loss, leading to improved satisfaction and treatment compliance by revealing positive changes visible within one month.

This meta-analysis found that while PRP therapy may result in higher patient satisfaction and better negative hair pull test results, it shows no clear advantage over minoxidil in terms of hair density or regrowth in androgenetic alopecia treatment.

This study concluded that platelet-rich plasma is nearly as effective as topical minoxidil for treating androgenetic alopecia, with PRP improving hair density and minoxidil boosting terminal hair count.

This review discusses the treatment strategies for androgenetic alopecia in men and reports no new clinical results; the authors emphasize the need to understand its multifactorial etiology.

This study found that platelet-rich plasma therapy may effectively treat androgenetic alopecia and could potentially replace topical minoxidil, offering promising results in terms of hair growth and patient satisfaction.

This study found that the combination of PRP with topical minoxidil and finasteride showed the most significant improvement in hair pull tests and patient satisfaction for male androgenetic alopecia, surpassing individual therapies and placebo over a six-month period.

This study reviewed randomized controlled trials to assess whether adding platelet-rich plasma injections to a Minoxidil regimen offers any benefit in treating androgenetic alopecia, but results are not reported in the abstract.

This systematic review examined 64 randomized controlled clinical trials on regenerative medicine for specific dermatologic disorders, reporting up to 68.4% improvement in androgenetic alopecia and up to 71% improvement in vitiligo among 2888 patients.

This meta-analysis suggests that combining platelet-rich plasma with minoxidil enhances hair growth and patient satisfaction more effectively than using either treatment alone for androgenetic alopecia.

This study found that platelet-rich plasma therapy may be a useful alternative to 5% topical minoxidil for treating androgenetic alopecia, with differences in the effectiveness and patient satisfaction outcomes observed.

This review suggests that combining PRP with minoxidil may be more effective for promoting hair growth in androgenetic alopecia than using either treatment alone, although study variations limit definitive conclusions.

This review examines the efficacy of various novel treatments for androgenetic alopecia, including oral minoxidil and platelet-rich plasma, suggesting potential benefits but emphasizing the need for further high-quality clinical trials to thoroughly evaluate their effectiveness.

In this study, activated platelet-rich plasma improved hair density and thickness in patients with androgenetic alopecia, with higher platelet counts enhancing these effects over time.

This study compared the effectiveness and safety of microneedling with PRP versus minoxidil and finasteride topical therapy in adult males with androgenetic alopecia, finding similar hair density improvements in both groups, though microneedling with PRP had a quicker onset of action.

In this study, researchers reported that treating alopecia areata patients with ritlecitinib led to progressive improvements in emotional symptoms and activity limitations over 48 weeks, though the post hoc analysis and trial setting suggest caution in interpreting the findings for broader populations.

In this study, researchers found that ritlecitinib 50 mg offered a lower cost per responder than baricitinib 2 or 4 mg at both 24 and 52 weeks for treating severe alopecia areata, suggesting potential implications for reimbursement or formulary decisions.